top bottom line well estim full year guidanc sale
ep rais ipo
ep estim consensu
ep guidanc rais prior rais
estim pt ep reflect increas
ep forecast improv visibl ep estim review
sale estim consensu product
beat estim includ humalog cymbalta strattera
trulic taltz cyramza verzenio olumi zyprexa effient combin
forecast product forecast includ jardianc light
tradjenta ciali alimta basaglar combin light anim health
sale estim sale guidanc rais
vs prior last publish revenu estim
gpm estim
estim sg forecast net non-
oper incom estim pre-tax margin
estim tax rate estim share count
estim ad full year guidanc
updat gpm approxim vs prior approx model rest
expect lilli announc plan spin-out equiti offer
less elanco share plan lilli divest remain ownership
view posit lilli focu core human pharma busi
elanco enabl concentr resourc attract anim health market
compani
verzenio eu/jp approv mbc ph ii data mbc w/
herceptin taltz file axspa galcanezumab cgrp approv migrain
prevent pdufa lasmiditan file migrain treatment olumi initi ph
sle cyramza top-lin data egfr nsclc relay jardianc initi ph
ckd full ph data easd posit top-lin tradjenta ph top-lin
ultra-rapid insulin ph top-lin data initi ph
late investor call easd earli oct alimta label updat
nsclc elanco ipo ye
pleas see page report import disclosur
number promis new drug rollout late-stag agent pois launch
next year give us confid top-tier sale ep growth prospect pipelin
visibl improv overal margin target appear achiev estim
ep compound-annual-growth-rate among best pharma dividend yield attract
perform diabet busi
galcanezumab approv migrain
revenu growth leverag
ep growth
declin alimta
temper keytruda/chemo
one four less visibl pipelin
candid gener
alimta declin rapidli
margin expans plan delay
margin expans sooner greater
compani global biopharmaceut compani incorpor
indiana two main segment human pharmaceut product anim health
product lead product area diabet metabol diseas
oncolog among other lilli anim health busi oper elanco anim
divis develop manufactur market product food companion
cowen compani
good mm cowen
cowen compani www lilli com
cowen compani
cowen compani
cowen compani
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
